20. Литература

Поставить закладку

1. Савченко В.Г., Паровичникова Е.Н. Лечение острых лейкозов. М.: Медицина; 2005.
2. Савченко В.Г., ред. Программное лечение заболеваний системы крови. М.: Практика; 2012: 155—245.
3. Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2011 году (Заболеваемость и смертность). М.; 2013: 125—30.
4. http: / / seer.cancer. gov/ statfacts/html/alyl .html
5. Swerdlow S., Campo E., Yarris N.L. et al., eds. WHO classification of tumors of hematopoietic and lymphoid tissues. Geneva: WHO PRESS; 2008: 110—55.
6. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al.; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453--74. doi: 10.1182/blood-2009-07-235358.
7. National Comprehensive Cancer Network (NCCN) GUIDELINES FOR AML TREATMENT Version 2.2013 http://www.nccn.org/professionals/physician gls/pdf/aml.pdf
8. Cornelissen J.J., Gratwohl A., Schlenk R.F., Sierra J., Bornhauser M., Juliusson G., et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat. Rev. Clin. Oncol. 2012; 9(10): 579—90. doi: 10.1038/nrclinonc.2012.150.
9. Buchner T., Schlenk R.F., Schaich M., Dohner K., Krahl R., Krauter J., et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm—combined prospective analysis by the German AML Intergroup. J. Clin. Oncol. 2012; 30(29): 3604—10. doi: 10.1200/JCO.2012.42.2907.
10. Juliusson G., Lazarevic V., Horstedt A.S., Hagberg O., Hoglund M.; Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012; 119(17): 3890—9. doi: 10.1182/blood-2011-12-379008.
11. Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., et al.; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013; 98(12): 1826—35. doi: 10.3324/haematol.2013.091025.
12. Averbuch D., Cordonnier C., Livermore D.M., Mikulska M., Orasch C., Viscoli C., et al.; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013; 98(12): 1836-47. doi: 10.3324/haematol.2013.091330.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница